Chiasma Stock Price, News & Analysis (NASDAQ:CHMA)

$1.55 +0.05 (+3.33 %)
(As of 02/19/2018 09:00 AM ET)
Previous Close$1.50
Today's Range$1.50 - $1.60
52-Week Range$1.25 - $2.95
Volume18,000 shs
Average Volume103,670 shs
Market Capitalization$37.79 million
P/E Ratio-1.32
Dividend YieldN/A
Beta1.15

About Chiasma (NASDAQ:CHMA)

Chiasma logoChiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CHMA
CUSIPN/A
Phone617-928-5300

Debt

Debt-to-Equity RatioN/A
Current Ratio9.66%
Quick Ratio9.66%

Price-To-Earnings

Trailing P/E Ratio-1.32477500192306
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.52 per share
Price / Book0.44

Profitability

Trailing EPS($1.17)
Net Income$-61,110,000.00
Net MarginsN/A
Return on Equity-36.49%
Return on Assets-32.48%

Miscellaneous

Employees17
Outstanding Shares24,380,000

Chiasma (NASDAQ:CHMA) Frequently Asked Questions

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

How were Chiasma's earnings last quarter?

Chiasma Inc (NASDAQ:CHMA) released its quarterly earnings results on Friday, May, 5th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.06. View Chiasma's Earnings History.

When will Chiasma make its next earnings announcement?

Chiasma is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for Chiasma.

Who are some of Chiasma's key competitors?

Who are Chiasma's key executives?

Chiasma's management team includes the folowing people:

  • David M. Stack, Independent Chairman of the Board (Age 66)
  • Mark J. Fitzpatrick, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director (Age 54)
  • Drew Enamait, Principal Accounting Officer, Vice President - Finance & Administration, Corporate Controller (Age 42)
  • Roni Mamluk Ph.D., Director (Age 50)
  • Todd Foley, Independent Director (Age 45)
  • Bard J. Geesaman M.D. Ph.D., Independent Director (Age 49)
  • Scott Minick, Independent Director (Age 65)
  • John A. Scarlett M.D., Independent Director (Age 66)

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Who owns Chiasma stock?

Chiasma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Rock Springs Capital Management LP (2.15%), Renaissance Technologies LLC (0.26%) and Deutsche Bank AG (0.25%). Company insiders that own Chiasma stock include Roni Mamluk and Scott Minick. View Institutional Ownership Trends for Chiasma.

Who bought Chiasma stock? Who is buying Chiasma stock?

Chiasma's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG and Rock Springs Capital Management LP. View Insider Buying and Selling for Chiasma.

How do I buy Chiasma stock?

Shares of Chiasma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chiasma's stock price today?

One share of Chiasma stock can currently be purchased for approximately $1.55.

How big of a company is Chiasma?

Chiasma has a market capitalization of $37.79 million. The biotechnology company earns $-61,110,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. Chiasma employs 17 workers across the globe.

How can I contact Chiasma?

Chiasma's mailing address is 275 WYMAN STREET SUITE 250, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]


MarketBeat Community Rating for Chiasma (CHMA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Chiasma (NASDAQ:CHMA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ASellSell
Consensus Rating Score: N/AN/A1.001.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Chiasma (NASDAQ:CHMA) Consensus Price Target History

Price Target History for Chiasma (NASDAQ:CHMA)

Chiasma (NASDAQ:CHMA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2017BarclaysDowngradeEqual Weight -> UnderweightN/AView Rating Details
5/13/2016CowenReiterated RatingHoldN/AView Rating Details
4/18/2016OppenheimerReiterated RatingOutperform$43.00 -> $9.00N/AView Rating Details
4/18/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Chiasma (NASDAQ:CHMA) Earnings History and Estimates Chart

Earnings by Quarter for Chiasma (NASDAQ:CHMA)

Chiasma (NASDAQ CHMA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.23)N/AView Earnings Details
11/9/2017Q3 2017($0.28)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.28)ViewN/AView Earnings Details
5/5/2017Q1 2017($0.23)($0.29)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.59)($0.30)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.73)($0.35)ViewN/AView Earnings Details
8/10/2016Q2($0.63)($0.83)ViewListenView Earnings Details
5/11/2016Q1($0.63)($0.71)ViewListenView Earnings Details
3/14/2016Q4($0.53)($0.61)ViewListenView Earnings Details
11/12/2015Q315($0.38)($0.46)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Chiasma (NASDAQ:CHMA) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Chiasma (NASDAQ:CHMA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Chiasma (NASDAQ CHMA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 55.02%
Insider Trades by Quarter for Chiasma (NASDAQ:CHMA)
Insider Trades by Quarter for Chiasma (NASDAQ:CHMA)

Chiasma (NASDAQ CHMA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017Roni MamlukDirectorSell2,389$1.75$4,180.752,389View SEC Filing  
10/24/2017Roni MamlukDirectorSell2,389$2.27$5,423.032,389View SEC Filing  
9/21/2017Scott MinickDirectorBuy25,000$2.37$59,250.00View SEC Filing  
9/20/2017Scott MinickDirectorBuy15,000$2.38$35,700.00View SEC Filing  
7/21/2015Health Ventures Lp 7-MedMajor ShareholderBuy93,750$16.00$1,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Chiasma (NASDAQ CHMA) News Headlines

Source:
DateHeadline
Contrasting Syndax Pharmaceuticals (SNDX) & Chiasma (CHMA)Contrasting Syndax Pharmaceuticals (SNDX) & Chiasma (CHMA)
www.americanbankingnews.com - February 10 at 11:10 PM
Sonoma Pharmaceuticals (SNOA) vs. Chiasma (CHMA) Head-To-Head ContrastSonoma Pharmaceuticals (SNOA) vs. Chiasma (CHMA) Head-To-Head Contrast
www.americanbankingnews.com - January 20 at 11:28 AM
Zacks: Chiasma Inc (CHMA) Receives Average Recommendation of "Strong Sell" from BrokeragesZacks: Chiasma Inc (CHMA) Receives Average Recommendation of "Strong Sell" from Brokerages
www.americanbankingnews.com - January 16 at 1:10 PM
Chiasma Reports on Significant Progress Made During 2017Chiasma Reports on Significant Progress Made During 2017
finance.yahoo.com - January 8 at 9:48 AM
 Chiasma, Inc. (CHMA) Receives Average Recommendation of "Strong Sell" from Analysts Chiasma, Inc. (CHMA) Receives Average Recommendation of "Strong Sell" from Analysts
www.americanbankingnews.com - December 16 at 11:10 PM
Critical Analysis: Chiasma (CHMA) vs. Catalyst Biosciences (CBIO)Critical Analysis: Chiasma (CHMA) vs. Catalyst Biosciences (CBIO)
www.americanbankingnews.com - December 1 at 11:16 AM
Zacks: Chiasma, Inc. (CHMA) Given Average Rating of "Strong Sell" by BrokeragesZacks: Chiasma, Inc. (CHMA) Given Average Rating of "Strong Sell" by Brokerages
www.americanbankingnews.com - November 24 at 11:16 AM
BRIEF-Chiasma Q3 loss per share $0.28BRIEF-Chiasma Q3 loss per share $0.28
www.reuters.com - November 11 at 11:31 AM
Chiasma Reports Third Quarter 2017 ResultsChiasma Reports Third Quarter 2017 Results
finance.yahoo.com - November 9 at 8:02 PM
Chiasma reports 3Q lossChiasma reports 3Q loss
finance.yahoo.com - November 9 at 8:02 PM
Is Chiasma Inc’s (CHMA) CEO Pay Fair?Is Chiasma Inc’s (CHMA) CEO Pay Fair?
finance.yahoo.com - November 7 at 8:09 PM
Chiasma, Inc. (CHMA) Scheduled to Post Quarterly Earnings on TuesdayChiasma, Inc. (CHMA) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
Head-To-Head Survey: Chiasma (CHMA) & VIVUS (VVUS)Head-To-Head Survey: Chiasma (CHMA) & VIVUS (VVUS)
www.americanbankingnews.com - October 25 at 4:27 AM
Chiasma (CHMA) vs. Its Competitors Financial SurveyChiasma (CHMA) vs. Its Competitors Financial Survey
www.americanbankingnews.com - October 23 at 8:30 AM
Comparing Chiasma (CHMA) & The CompetitionComparing Chiasma (CHMA) & The Competition
www.americanbankingnews.com - October 23 at 2:08 AM
Head-To-Head Comparison: Chiasma (CHMA) versus Its PeersHead-To-Head Comparison: Chiasma (CHMA) versus Its Peers
www.americanbankingnews.com - October 17 at 4:08 AM
Financial Comparison: Opiant Pharmaceuticals (OPNT) versus Chiasma (CHMA)Financial Comparison: Opiant Pharmaceuticals (OPNT) versus Chiasma (CHMA)
www.americanbankingnews.com - October 15 at 8:28 PM
Chiasma, Inc. (CHMA) Sees Significant Drop in Short InterestChiasma, Inc. (CHMA) Sees Significant Drop in Short Interest
www.americanbankingnews.com - October 15 at 2:20 AM
BioMarin Pharmaceutical (BMRN) vs. Chiasma (CHMA) Head-To-Head ContrastBioMarin Pharmaceutical (BMRN) vs. Chiasma (CHMA) Head-To-Head Contrast
www.americanbankingnews.com - October 13 at 12:26 AM
Critical Analysis: Chiasma (CHMA) & KalVista Pharmaceuticals (KALV)Critical Analysis: Chiasma (CHMA) & KalVista Pharmaceuticals (KALV)
www.americanbankingnews.com - October 12 at 2:32 PM
AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls BackAERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back
www.rttnews.com - October 11 at 11:40 PM
Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with AcromegalyChiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly
finance.yahoo.com - October 2 at 4:44 PM
Chiasma, Inc. (CHMA) Reports First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide ... - StreetInsider.comChiasma, Inc. (CHMA) Reports First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide ... - StreetInsider.com
www.streetinsider.com - September 29 at 8:17 AM
Phase 3 MPOWERED Trial Surpasses 50% Patients RandomizedPhase 3 MPOWERED Trial Surpasses 50% Patients Randomized
www.thestreet.com - September 28 at 10:10 PM
Reviewing Chiasma (CHMA) and Its PeersReviewing Chiasma (CHMA) and Its Peers
www.americanbankingnews.com - September 26 at 8:22 PM
Chiasma, Inc. (CHMA) Director Scott Minick Acquires 15,000 SharesChiasma, Inc. (CHMA) Director Scott Minick Acquires 15,000 Shares
www.americanbankingnews.com - September 22 at 8:38 PM
Chiasma, Inc. (CHMA) Director Buys $59,250.00 in StockChiasma, Inc. (CHMA) Director Buys $59,250.00 in Stock
www.americanbankingnews.com - September 22 at 8:38 PM
Critical Comparison: Chiasma (CHMA) versus ChemoCentryx (CCXI)Critical Comparison: Chiasma (CHMA) versus ChemoCentryx (CCXI)
www.americanbankingnews.com - September 8 at 6:10 AM
Head-To-Head Survey: Chiasma (CHMA) and Vitae Pharmaceuticals (VTAE)Head-To-Head Survey: Chiasma (CHMA) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - August 23 at 12:20 PM
Chiasma, Inc. (CHMA) Announces Agreement with FDA Under SPA for New Phase 3 Clinical Trial of Octreotide Capsules in AcromegalyChiasma, Inc. (CHMA) Announces Agreement with FDA Under SPA for New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
www.streetinsider.com - August 12 at 4:43 PM
Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in AcromegalyChiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
finance.yahoo.com - August 10 at 6:25 PM
Chiasma Reports Second Quarter 2017 ResultsChiasma Reports Second Quarter 2017 Results
finance.yahoo.com - August 10 at 6:25 PM
Chiasma reports 2Q lossChiasma reports 2Q loss
finance.yahoo.com - August 10 at 6:25 PM
Chiasma, Inc. (NASDAQ:CHMA) Set to Announce Quarterly Earnings on TuesdayChiasma, Inc. (NASDAQ:CHMA) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:16 AM
Head to Head Review: Alimera Sciences (ALIM) vs. Chiasma (NASDAQ:CHMA)Head to Head Review: Alimera Sciences (ALIM) vs. Chiasma (NASDAQ:CHMA)
www.americanbankingnews.com - July 10 at 12:14 AM
Chiasma (CHMA) Announces Poster Presentation at ENDO - StreetInsider.comChiasma (CHMA) Announces Poster Presentation at ENDO - StreetInsider.com
www.streetinsider.com - March 31 at 2:43 AM
Chiasma (CHMA) Announces Poster Presentation at ENDOChiasma (CHMA) Announces Poster Presentation at ENDO
www.streetinsider.com - March 30 at 9:43 PM
Chiasma Reports Fourth Quarter and Year End 2016 ResultsChiasma Reports Fourth Quarter and Year End 2016 Results
us.rd.yahoo.com - March 16 at 10:37 PM
CHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsCHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 10:37 PM
Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017
us.rd.yahoo.com - January 9 at 5:25 PM
8:14 am Chiasma reviews 2016, provides preliminary outlook for 20178:14 am Chiasma reviews 2016, provides preliminary outlook for 2017
us.rd.yahoo.com - January 9 at 5:25 PM
CHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements anCHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements an
biz.yahoo.com - January 9 at 5:25 PM

SEC Filings

Chiasma (NASDAQ:CHMA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Chiasma (NASDAQ:CHMA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Chiasma (NASDAQ CHMA) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.